⌕
Revolution Medicines · RVMD · Nasdaq
Tenet 39 · Weak
Compare
$162.69−2.50%At closeTenet 39 · Weak
$162.69−4.18 (−2.50%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$163.55+0.86 (+0.53%)
After hours: Nov 17, 2026, 6:06 PM ET

Revolution Medicines (RVMD) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 67% below its peak (through FY23), net margin −3768.3%. Worth your attention in FY25: Share count (+161.1%) and Capex step-up ($16.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼88.5%
−1,131.3
FY21→FY25CAGR —
Free cash flow ($M)▼60.9%
−913.7
capex stepped upCAGR —
Diluted EPS▼66.2%
−5.95
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+161.1%

72.8mn → 190.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$16.0M

▲55% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−987.3R&D−195.0SG&A−1182.4Op income51.1Tax & other−1131.3Net income

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
197,559.00.00.011,580.035,380.029,390.0——
Cost of revenue
327.00.00.00.00.00.0——
Gross profit
197,232.00.00.0—A—A29,390.0——
Research & development
1,450,919.0987,332.0592,225.0423,144.0253,073.0186,948.0▲66.7%+51.6%
Selling, general & admin
431,442.0195,037.097,299.075,621.040,586.030,450.0▲100.5%+59.1%
Total operating expenses
1,882,361.01,182,369.0689,524.0498,765.0293,659.0217,398.0▲71.5%+52.7%
Operating incomefeeds ROC rank
−1,685,129.0−1,182,369.0−689,524.0−487,185.0−258,279.0−188,008.0▼71.5%—
Other income, net
−187,760.051,068.088,678.047,294.09,154.0917.0——
Pretax income
−1,872,889.0−1,131,301.0−600,846.0−439,891.0−249,125.0−187,091.0▼88.3%—
Income tax
—0.0−753.0−3,524.0−420.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−1,870,536.0−1,131,301.0−600,093.0−436,367.0−248,705.0−187,091.0▼88.5%—
Per share
Diluted EPSbuyback-sensitive
−9.15−5.95−3.58−3.86−3.08−2.57▼66.2%—
Diluted shares (mn)
214.95190.13167.74113.1580.6372.81▲13.3%+27.1%
Margins
Gross margin99th pct in Healthcare
99.8%———A—A100.0%——
Operating margin
−853.0%——−4207.1%−730.0%−639.7%——
Net margin1st pct in Healthcare
−946.8%——−3768.3%−703.0%−636.6%——
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.